Percutaneous treatment of native coarctation (coA), gold standard in adult patients, is still debated in children. We aim to report the French multicentre experience.

All patients aged 1 to 18 yrs with native coA, treated percutaneously between 01/2000 and 12/2018, were included in this multcentric (9 centres) retrospective survey.

One hundred and thirty three children (34 female) were included. Indication for treatment was hypertension in 109, exercise hypertension in 8 and other reasons in 16 patients. Mean age at intervention was 11.5±3.9 years, mean weight 41±18kg. Procedure consisted of isolated balloon dilatation in 5 (mean age 2,63 yrs, mean weight 12kg), balloon dilatation followed by stent implantation in 8 (mean age 11 yrs, mean weight 37kg), and immediate stent implantation in 120 (mean age 12 yrs, mean weight 43kg). Stents used (n=124/128) were covered in 43, non-covered in 77, including 38 open cell stents. Invasive gradient across coA dropped from 28mmHg (range 5 to 64) at baseline (n=124) to 3mmHg (range -5 to 20) after intervention (n= 105). Three associated lesions were treated: 1 PDA closure, 1 aortic valvuloplasty and 1 left SVC occlusion. Serious vascular complications occurred in 8 patients (6%) (3 pseudo-aneurysms, 2 dissections, 2 stenosis and 1 occlusion) requiring surgery in 2. Reintervention was performed in 22%: 2 patients had surgery, 28 were treated percutaneously (14 balloon dilatations, 14 stent implantations). Mean follow-up reached 4.9±4.7 years. At latest follow-up, 25% remained hypertensive with 15 patients (11%) on anti-hypertensive medication. MRI, CTscan or fluoroscopy imaging, are available in 52 patients during follow-up (39%). Rate of aneurysm formation, stent fracture and risks factors for reintervention or residual hypertension will be presented.

Percutaneous treatment of native coarctation was safe and efficient in our french population. Close follow-up is required for longer-term results.